Tricuspid TEER: learnings from the 2-year outcomes of TRILUMINATE Pivotal trial & bRIGHT study

At EuroPCR 2025, Marianna Adamo and Ralph Stephan von Bardeleben discussed the latest findings on tricuspid valve repair using transcatheter edge-to-edge repair (TEER).

The 2-year results from the TRILUMINATE Pivotal trial showed a significant reduction in tricuspid regurgitation, lasting improvements in quality of life, and a notable decrease in heart failure hospitalizations. These positive outcomes were supported by the bRIGHT registry, a large single-arm study of over 500 patients treated with the TriClip device in routine clinical practice.

The discussion also covers which patients may benefit most from TEER, how these results are viewed by the heart failure community, and whether the approach to tricuspid valve repair is changing. Learn more about these important developments and the growing role of TEER in managing tricuspid valve disease.

This interview was filmed at EuroPCR 2025: see more videos here.